Pancreatic Cancer Clinical Trial
— ADPACAOfficial title:
Austrian Registry for Evaluation of Treatment Patterns and Outcome in Patients With Advanced Pancreatic Ductal Adenocarcinoma (PDAC)
NCT number | NCT05526443 |
Other study ID # | ADPACA |
Secondary ID | |
Status | Recruiting |
Phase | |
First received | |
Last updated | |
Start date | January 13, 2023 |
Est. completion date | October 2025 |
To systematically collect and analyse real-world data on treatment patterns, clinical outcomes and toxicities among patients with advanced pancreatic ductal adenocarcinoma (PDAC) undergoing systematic treatment in Austria
Status | Recruiting |
Enrollment | 1000 |
Est. completion date | October 2025 |
Est. primary completion date | October 2025 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: - 18 years, female and male - ECOG (Eastern Cooperative Oncology Group) Scale 0-2 - Diagnosis of histologically confirmed locally advanced inoperable and/or metastatic PDAC - Patients undergoing palliative 1st line chemotherapy - Signed informed consent for prospective patients, for retrospective cases no informed consent is required Exclusion Criteria: - Patients with locally advanced operable PDAC who do not receive palliative chemotherapy - Patients with locally advanced borderline resectable PDAC who do not receive palliative chemotherapy |
Country | Name | City | State |
---|---|---|---|
Austria | Medical University Graz Department of Oncology | Graz | Styria |
Lead Sponsor | Collaborator |
---|---|
Medical University of Graz | Krankenhaus Barmherzige Schwestern Linz, LKH Klagenfurt, Medical University Innsbruck, Medical University of Vienna |
Austria,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Proportion of patients with locally advanced inoperable and/or metastatic PDAC undergoing palliative second line therapy after progression on first line chemotherapy | 24 months | ||
Secondary | To identify prognostic and predictive features for treatment efficacy | 24 months | ||
Secondary | To identify prognostic and predictive features for clinical outcome | 24 months | ||
Secondary | To identify prognostic and predictive features for Neuropathy | Relative frequency of Grade 3 and Grade 4 Adverse Events according to the Common Terminology Criteria of Adverse Events (CTCAE) will be documented | 24 months | |
Secondary | To identify prognostic and predictive features for Febrile Neuropathy | Relative frequency of Grade 3 and Grade 4 Adverse Events (CTCAE) will be documented | 24 months | |
Secondary | To identify prognostic and predictive features for Thrombocytopenia | Relative frequency of Grade 3 and Grade 4 Adverse Events (CTCAE) will be documented | 24 months | |
Secondary | To identify prognostic and predictive features for Anemia | Relative frequency of Grade 3 and Grade 4 Adverse Events (CTCAE) will be documented | 24 months | |
Secondary | To identify prognostic and predictive features for Nausea/Vomiting | Relative frequency of Grade 3 and Grade 4 Adverse Events (CTCAE) will be documented | 24 months | |
Secondary | To identify prognostic and predictive features for Skin toxicity | Relative frequency of Grade 3 and Grade 4 Adverse Events (CTCAE) will be documented | 24 months | |
Secondary | To identify prognostic and predictive features for rash | Relative frequency of Grade 3 and Grade 4 Adverse Events (CTCAE) will be documented | 24 months | |
Secondary | To identify prognostic and predictive features for mucositis | Relative frequency of Grade 3 and Grade 4 Adverse Events (CTCAE) will be documented | 24 months | |
Secondary | To identify prognostic and predictive features for Fatigue | Relative frequency of Grade 3 and Grade 4 Adverse Events (CTCAE) will be documented | 24 months | |
Secondary | To identify prognostic and predictive features for Allergic reactions | Relative frequency of Grade 3 and Grade 4 Adverse Events (CTCAE) will be documented | 24 months | |
Secondary | To identify prognostic and predictive features for all other Adverse Events | Relative frequency of Grade 3 and Grade 4 Adverse Events (CTCAE) will be documented | 24 months | |
Secondary | To investigate the effect of dose density on treatment efficacy of first- and second line therapy | 24 months | ||
Secondary | To investigate the effect of dose modifications on treatment efficacy of first- and second line therapy | 24 months | ||
Secondary | To perform a comparative effectiveness analysis of different palliative second line chemotherapy regimens | 24 months | ||
Secondary | To evaluate treatment behaviours after progression on palliative second line therapy | 24 months | ||
Secondary | To analyse efficacy of palliative third line therapy | 24 months | ||
Secondary | To analyse patterns of BRCA testing in real-world practice | 24 months | ||
Secondary | To analyse the impact of BRCA testing in real-world practice on treatment decisions | 24 months | ||
Secondary | To analyse the impact of BRCA testing in real-world practice on outcome | 24 months | ||
Secondary | Prevalence of primary tumor resection in patients with metastatic or locally advanced inoperable pancreatic cancer | 24 months | ||
Secondary | Prevalence of metastasectomy in patients with metastatic or locally advanced inoperable pancreatic cancer | 24 months | ||
Secondary | To evaluate the impact of primary tumor resection on outcome | 24 months | ||
Secondary | To evaluate the impact of metastasectomy on outcome | 24 months | ||
Secondary | To evaluate the impact of primary granulocyte-colony stimulating factor (G-CSF) use on dose density of FOLFIRINOX | 24 months | ||
Secondary | To evaluate the impact of primary granulocyte-colony stimulating factor (G-CSF) use on rate of febrile neutropenia | 24 months | ||
Secondary | To evaluate the impact of primary granulocyte-colony stimulating factor (G-CSF) use on overall outcome | 24 months | ||
Secondary | To evaluate patterns of molecular profiling in the real world treatment practice of advanced pancreatic cancer | 24 months | ||
Secondary | To evaluate patterns of next generation sequencing (NGS) in the real world treatment practice of advanced pancreatic cancer | 24 months | ||
Secondary | To analyse treatment patterns and outcome in the subgroup of very young (<40 years old) patients with advanced pancreatic cancer | 24 months | ||
Secondary | To analyse treatment patterns and outcome in the subgroup of very old (>75 years old) patients with advanced pancreatic cancer | 24 months | ||
Secondary | To investigate the impact of diabetes mellitus on treatment efficacy of palliative chemotherapy and disease outcome | 24 months | ||
Secondary | To investigate the impact of antidiabetic therapy on treatment efficacy of palliative chemotherapy and disease outcome | 24 months | ||
Secondary | To analyze the mutational landscape of advanced pancreatic cancer and its impact on treatment decision making and clinical outcome | 24 months |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT05305001 -
Germline Mutations Associated With Hereditary Pancreatic Cancer in Unselected Patients With Pancreatic Cancer in Mexico
|
||
Completed |
NCT02526017 -
Study of Cabiralizumab in Combination With Nivolumab in Patients With Selected Advanced Cancers
|
Phase 1 | |
Recruiting |
NCT05497531 -
Pilot Comparing ctDNA IDV vs. SPV Sample in Pts Undergoing Biopsies for Hepatobiliary and Pancreatic Cancers
|
N/A | |
Recruiting |
NCT06054984 -
TCR-T Cells in the Treatment of Advanced Pancreatic Cancer
|
Early Phase 1 | |
Recruiting |
NCT04927780 -
Perioperative or Adjuvant mFOLFIRINOX for Resectable Pancreatic Cancer
|
Phase 3 | |
Recruiting |
NCT05919537 -
Study of an Anti-HER3 Antibody, HMBD-001, With or Without Chemotherapy in Patients With Solid Tumors Harboring an NRG1 Fusion or HER3 Mutation
|
Phase 1 | |
Terminated |
NCT03140670 -
Maintenance Rucaparib in BRCA1, BRCA2 or PALB2 Mutated Pancreatic Cancer That Has Not Progressed on Platinum-based Therapy
|
Phase 2 | |
Terminated |
NCT00529113 -
Study With Gemcitabine and RTA 402 for Patients With Unresectable Pancreatic Cancer
|
Phase 1 | |
Recruiting |
NCT05168527 -
The First Line Treatment of Fruquintinib Combined With Albumin Paclitaxel and Gemcitabine in Pancreatic Cancer Patients
|
Phase 2 | |
Active, not recruiting |
NCT04383210 -
Study of Seribantumab in Adult Patients With NRG1 Gene Fusion Positive Advanced Solid Tumors
|
Phase 2 | |
Recruiting |
NCT05391126 -
GENOCARE: A Prospective, Randomized Clinical Trial of Genotype-Guided Dosing Versus Usual Care
|
N/A | |
Terminated |
NCT03300921 -
A Phase Ib Pharmacodynamic Study of Neoadjuvant Paricalcitol in Resectable Pancreatic Cancer A Phase Ib Pharmacodynamic Study of Neoadjuvant Paricalcitol in Resectable Pancreatic Cancer
|
Phase 1 | |
Completed |
NCT03153410 -
Pilot Study With CY, Pembrolizumab, GVAX, and IMC-CS4 (LY3022855) in Patients With Borderline Resectable Adenocarcinoma of the Pancreas
|
Early Phase 1 | |
Recruiting |
NCT03175224 -
APL-101 Study of Subjects With NSCLC With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors
|
Phase 2 | |
Recruiting |
NCT05679583 -
Preoperative Stereotactic Body Radiation Therapy in Patients With Resectable Pancreatic Cancer
|
Phase 2 | |
Recruiting |
NCT04183478 -
The Efficacy and Safety of K-001 in the Treatment of Advanced Pancreatic Cancer
|
Phase 2/Phase 3 | |
Terminated |
NCT03600623 -
Folfirinox or Gemcitabine-Nab Paclitaxel Followed by Stereotactic Body Radiotherapy for Locally Advanced Pancreatic Cancer
|
Early Phase 1 | |
Recruiting |
NCT04584008 -
Targeted Agent Evaluation in Digestive Cancers in China Based on Molecular Characteristics
|
N/A | |
Recruiting |
NCT05351983 -
Patient-derived Organoids Drug Screen in Pancreatic Cancer
|
N/A | |
Completed |
NCT04290364 -
Early Palliative Care in Pancreatic Cancer - a Quasi-experimental Study
|